Loading
A fifth of patients with solid tumours develop brain metastases and are usually excluded from trials. This would fund a programme that studies and treats them as a disease in their own right.
A funded network of brain-metastasis centres runs dedicated trials (systemic agents with CNS activity, radiosurgery sequencing, prevention in high-risk groups such as HER2-positive breast and EGFR/ALK lung cancer), builds a shared registry and tissue bank of resected metastases, and develops CNS-specific endpoints accepted by regulators. Funders and regulators would jointly discourage the routine exclusion of patients with stable brain metastases from registration trials.
One of the most cited trial reports Europe PMC returns for Osimertinib in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Anyone diagnosed with advanced lung cancer should have EGFR testing before treatment, because osimertinib as the first drug gives the longest disease control, protects the brain, and is well tolerated. Chemotherapy is not the first step for these patients. The remaining questions are whether to intensify upfront (adding chemotherapy or amivantamab) and how to treat resistance when it develops.
One of the most cited trial reports Europe PMC returns for Osimertinib in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One bottleneck page and eight idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Measure brain metastasis prevention as a primary endpoint, not as a secondary one, Tucatinib, The brain: barrier and sanctuary, Osimertinib.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Measure brain metastasis prevention as a primary endpoint, not as a secondary one, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Tucatinib, The brain: barrier and sanctuary.
Shares The brain: barrier and sanctuary, Glioma & glioblastoma, HER2-positive breast cancer, Melanoma.
Shares The brain: barrier and sanctuary, HER2-positive breast cancer, Melanoma, Non-small-cell lung cancer.
Shares Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib, Non-small-cell lung cancer.